Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-09-16
Buyer: Oslo Universitetssykehus HF (hovedenhet)
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 26400000 NOK
Award criteria: The most economic tender

Technical requirements: Oslo University Hospital, the Child and Youth Clinic, Newborn Screening, has been given resources from Helse Sør Øst for the procurement of a NGS system. The newborn screening is organised as a national treatment service and regulated by 2 regulations:
2) Regulations No 1706 dated 17.12.2010 on the certification of hospitals, use of the term university hospital and national services in the specialist health service.
Approx. 60 000 newborns per annum are tested for 25 serious congenital disorders. According to the mandate for national treatment services, a new system must be used for better newborn screening, further development of the offer and research.
Oslo University Hospital, the Child and Youth Clinic, Newborn Screening, has been given resources from Helse Sør Øst for the procurement of a NGS system. The newborn screening is organised as a national treatment service and regulated by 2 regulations:
2) Regulations No 1706 dated 17.12.2010 on the certification of hospitals, use of the term university hospital and national services in the specialist health service.
Approx. 60 000 newborns per annum are tested for 25 serious congenital disorders. According to the mandate for national treatment services, a new system must be used for better newborn screening, further development of the offer and research.
3) The newborn screening needs a system that can sequence and analyse large gene panels (bioinformatic filtered), human coded genes, genomes, and transcriptomes at the same time in order to solve different problems. In order to reduce response times and costs, it is important that these can be run together. The department has the national treatment service for genetic mass examinations, and needs flexible and considerable capacity for quick analyses in its routines, further development and research. The service is an emergency help service with considerable requirements for quick analysis and response time in order to ensure correct disease clarification and follow-up of children with serious congenital disorders. We work towards genetic disorder clarification within 24-36 hours from when the screening sample is received. The instrument must be able to handle different protocols in order to cover all needs within routines and research. The system must be able to sequence from both PCR-free sample preparation and PCR-based sample preparation. It is very important that the sample preparation is flexible and can be automated with an option to split up protocols. The department has Hamilton and Beckman Biomek pipetting robots for this task. Different protocols will be optimal with different read lengths for different purposes. Short reads give quick and cheap answers, longer reads give greater possibilities for the detection of pseudogenes and structural variants. The system must be flexible as regards sequencing protocols and read lengths — from 50 to 250 bp runs. Output data from the system must be compatible with standard bioinformatic tools/pipelines for analysis and interpretation of data (for example GATK best practice). The basis is that Illumina is the only supplier that, due to technical reasons, can deliver in accordance with the requirements. The voluntary ex-ante transparency notice is pursuant to the public procurement regulations § 21-5. The terms in FOA § 13-4 (2) and 13-1 (5) are deemed to be fulfilled, as well as the value of the full service contract and the contract for consumables for the equipment's lifetime. (The expected lifetime is 5 years).
Oslo University Hospital, the Child and Youth Clinic, Newborn Screening, has been given resources from Helse Sør Øst for the procurement of a NGS system.
The newborn screening is organised as a national treatment service that is regulated by 2 regulations:
2) Regulation No 1706 dated 17.12.2010 on the certification of hospitals, use of the term university hospital and national services in the specialist health service.
Approx. 60 000 newborns per annum are tested for 25 serious congenital disorders. According to the mandate for national treatment services, a new system must be used for better newborn screening, further development of the offer and research.
The newborn screening needs a system that can sequence and analyse large gene panels (bioinformatic filtered), human coded genes, genomes, and transcriptomes at the same time in order to solve different problems. In order to reduce response times and costs, it is important that these can be run together. The department has the national treatment service for genetic mass examinations, and needs flexible and considerable capacity for quick analyses in its routines, further development and research. The service is an emergency help service with considerable requirements for quick analysis and response time in order to ensure correct disease clarification and follow-up of children with serious congenital disorders. We work towards genetic disorder clarification within 24-36 hours from when the screening sample is received. The instrument must be able to handle different protocols in order to cover all needs within routines and research. The system must be able to sequence from both PCR-free sample preparation and PCR-based sample preparation. It is very important that the sample preparation is flexible and can be automated with an option to split up protocols. The department has Hamilton and Beckman Biomek pipetting robots for this task. Different protocols will be optimal with different read lengths for different purposes. Short reads give quick and cheap answers, longer reads give greater possibilities for the detection of pseudogenes and structural variants. The system must be flexible as regards sequencing protocols and read lengths — from 50 to 250 bp runs. Output data from the system must be compatible with standard bioinformatic tools/pipelines for analysis and interpretation of data (for example GATK best practice). The basis is that Illumina is the only supplier that, due to technical reasons, can deliver in accordance with the requirements. The intention notice is pursuant to the public procurement regulations § 21-5. The terms in FOA § 13-4 (2) and 13-1 (5) are deemed to be fulfilled, as well as the value of the full service contract and the contract for consumables for the equipment's lifetime.


Winner: Illumina Norway AS
Award value: 26400000